Happenings Archive

What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.


Capricor Lands $13M Collaboration with Janssen, Gives Option to License Worth $325M
Jan 6, 2014
Capricor (CAPR) announced a manufacturing collaboration for its CAP-1002 allogeneic cardiac stem cells with Johnson & Johnson family member, Janssen Biotech, which will pay Capricor $12.5M up front. Janssen earns an exclusive option to license CAP-1002, worth a potential $325M plus royalties. CAPR shares were up nearly 30% on the announcement.
Capricor Therapeutics Completes Merger, Joins SCSI
Nov 22, 2013
Capricor Inc., developer of allogeneic cardiac stem cells for acute myocardial infarction, announced completion of its reverse merger with Nile Therapeutics. Following its 1-for-50 reverse stock split, the new Capricor Therapeutics will trade under the OTC Markets symbol NLTXD initially, changing to CAPR on Dec. 20th. Capricor Therapeutics thus becomes the 18th and newest component of the SCSI.
Capricor One Step Closer to Reverse Merger and Public Trading
Nov 14, 2013
Cardiac stem cell developer Capricor, Inc. (not a SCSI component company) moved closer to completing its proposed reverse merger with failed Nile Therapeutics (OTCMKTS:NLTX) this week when the latter's shareholders approved critical terms of the proposed deal, which would provide Capricor with much-needed access to public capital markets to fund its clinical trials.
Capricor moves to join publicly traded U.S. stem cell companies
Jul 8, 2013
Capricor, Inc., developing cardiac stem cells for heart attack, has proposed a reverse merger with penny stock Nile Therapeutics. If approved by shareholders, this could enable the company to better compete for scarce capital with cardiac-focused SCSI components Aastrom, Cytomedix, Cytori, Neostem and Osiris
< Previous Page  |  Next Page >